Among these previously reported protein biomarkers, MMP9 was included in our target list (Nadarajah et al, 2011); however, the elevated levels of MMP9 in DMD patients compared to BMD patients were revealed only in plasma samples from a single clinical site and could not be confirmed in serum or in the other plasma cohorts. This evidence concerns the gene MMP9 and Duchenne muscular dystrophy.